Zenas BioPharma, Inc. Debt Securities, Available-for-sale, Amortized Cost
Zenas BioPharma, Inc. (ZBIO) had Debt Securities, Available-for-sale, Amortized Cost of $478.25 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-13
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $478.25M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $218.47M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $249.64M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $185.93M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $478.25M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $218.47M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $249.64M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $185.93M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $230.96M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $117.62M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $30.99M 10-K · filed 2026-03-16 |
| 2024-09-30 | $26.70M 10-Q · filed 2024-11-12 |